With Large Biosimilars Opportunity In Sight, Multinational Companies Open Dialogue With India’s Wockhardt
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Adversities are throwing up unexpected opportunities for the debt-ridden Indian drug maker Wockhardt. While the company is being helped to tide over its unprecedented financial crisis of $600 million in debts by a group of large Indian banks, strategic opportunities in its biotech businesses have now come to surface